Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
efalizumab · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| efalizumab | DRUG | - |
Inclusion Criteria: * Signed informed consent * Plaque psoriasis covering \>=10% of total BSA * Plaque psoriasis diagnosed for at least 6 months * In the opinion of the investigator, a candidate for systemic therapy for psoriasis * 18-75 years old * Body weight \<=125 kg * For women of childbearing...
Top 12 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Johnson & Johnson | JNJ | 11 | PHASE3 | JNJ-77242113, Ustekinumab, Guselkumab |
| Bristol-Myers Squibb Company | BMY | 14 | PHASE3 | Deucravacitinib |
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Risankizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 3 | PHASE3 | Zasocitinib |
| Alumis Inc. | ALMS | 2 | PHASE3 | Envudeucitinib |
| Oruka Therapeutics, Inc. | ORKA | 4 | PHASE2 | ORKA-002, ORKA-001 |
| Can-Fite Biopharma Ltd | CANF | 1 | PHASE3 | Piclidenoson |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | Ponesimod |
| Novartis AG Sponsored ADR | NVS | 4 | - | Secukinumab |
| Bausch Health Companies Inc. | BHC | 2 | - | Brodalumab |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-8644 |
Efalizumab is a monoclonal antibody developed for the treatment of plaque psoriasis in adults. It was studied in patients with plaque psoriasis, including those receiving concomitant antipsoriatic therapies. Efalizumab is an investigational therapy that has been evaluated in clinical development for this dermatologic condition.
Efalizumab targets ITGAL and ITGB2, which are components of the lymphocyte function-associated antigen-1 (LFA-1) integrin. By binding to these targets, efalizumab acts as an inhibitor of LFA-1-mediated interactions. This mechanism is designed to interfere with T-cell activation and migration, processes involved in the pathophysiology of plaque psoriasis.
Efalizumab is being developed by Roche Holding AG, which trades under the ticker RHHBY. Roche is the company responsible for the clinical development of this monoclonal antibody for psoriasis.
Efalizumab is in Phase 3 clinical development for plaque psoriasis. It is an investigational agent and has not been approved by the FDA for any indication. The Phase 3 program has been completed, with one completed trial involving 1,200 participants.
Efalizumab has been studied in a Phase 3 clinical trial identified as NCT00338143. This completed study evaluated efalizumab in adults with plaque psoriasis, including those receiving concomitant antipsoriatic therapies. The trial enrolled 1,200 participants aged 18 years and older and was an uncontrolled study.